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Background:  We investigated the prevalence of diabetic autonomic neuropathy (DAN) and vestibular dysfunction (VD) in dia-
betic patients with peripheral neuropathy.
Methods:  Thirty-five diabetic patients with peripheral neuropathy were enrolled from August 2008 to July 2009. All subjects 
underwent autonomic function tests. Nineteen of the patients (54.3%) underwent videonystagmography.
Results:  Diabetic autonomic neuropathy was observed in 28 patients (80%). A mild degree of autonomic failure was observed 
in 18 patients (64.3%), and a moderate degree of autonomic failure was observed in ten patients (35.7%). Factors related to DAN 
included diabetic nephropathy (P=0.032), degree of chronic kidney disease (P=0.003), and duration of diabetes (P=0.044). Ves-
tibular dysfunction was observed in 11 of 19 patients (57.9%). There was no significant association between DAN and VD.
Conclusion:  Diabetic autonomic neuropathy was observed in 28 diabetic patients (80%) with peripheral neuropathy. Vestibular 
dysfunction was observed in nearly 60% of diabetic patients with peripheral neuropathy who complained of dizziness but showed 
no significant association with DAN. Diabetic patients who complained of dizziness need to examine both autonomic function 
and vestibular function.
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INTRODUCTION
Diabetic autonomic neuropathy (DAN) is a type of diabetic 
polyneuropathy, usually accompanied by diabetic peripheral 
neuropathy [1,2]. Diabetic autonomic neuropathy is associated 
with the duration of the disease as well as poor glycemic con-
trol and has a negative effect on quality of life and life expec-
tancy in affected patients [3,4].
  Previous reports indicated that the vestibular system is in-
volved in autonomic neural control for blood pressure and res-
piration according to positional change [5,6]. Vestibular dys-
function (VD) is a common comorbidity in patients with dia-
betes. Klagenberg et al. [7] reported a VD prevalence rate of 
60% in a survey of 30 subjects with type I diabetes. Gawron et 
al. [8] reported that children and young adults with type I dia-
betes were vulnerable to VD, and VD prevalence was signifi-
cantly higher in diabetic individuals than non-diabetic indi-
viduals [7-9]. Vestibular function plays an important role in 
postural stability with upright posture, along with the somatic 
and visual systems. Thus, VD increases the risk of falls due to 
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postural instability when walking, especially when it is accom-
panied by diabetic peripheral neuropathy [10,11].
  It is likely that diabetic patients with peripheral neuropathy 
will experience worsened symptoms or signs of the disorder 
when accompanied by DAN or VD. We investigated the prev-
alence and clinical significance of concomitant DAN and VD 
in patients with diabetic peripheral neuropathy.
METHODS
Subjects
From October 2008 to July 2009, we retrospectively investigat-
ed 35 patients who, based on their medical records, had been 
diagnosed with diabetic peripheral neuropathy. All patients had 
received autonomic and vestibular function tests in Gyeong-
sang National University Hospital. We also investigated age, 
sex, height, weight, body mass index (BMI), cigarette smoking, 
alcohol consumption, diabetes type, duration of diabetes, pres-
ence of microvascular complications and hypertension in all 
subjects.
  We excluded patients with diseases that could possibly cause 
peripheral neuropathy as well as disorders influencing auto-
nomic function such as: 1) severe neuropathy involved with 
paresis, muscle atrophy, or vibratory/heat sensory dysfunction 
on at least five areas including bilateral first toes, first metatar-
sal bones, or dorsa of the feet; 2) peripheral arterial obstructive 
disease; 3) alcoholic neuropathy or chronic alcohol abuse; 4) 
drug history potentially related to neuropathy (cisplatin, taxol) 
or exerting substantial influence on the result of the survey 
(antidepressants, anticonvulsants, opiates, neuroleptics); 5) 
neuropathy due to a malignant tumor, Parkinson’s disease, epi-
lepsy, multiple sclerosis, spinal stenosis, vitamin B12 deficien-
cy, or leprosy; 6) panhypopituitarism or hypothyroidism; 7) 
pheochromocytoma; 8) congestive heart failure or amyloido-
sis; or 9) other severe diseases (cancer, liver cirrhosis, chronic 
hepatitis, GOT/GPT ≥80 IU/L, serum creatinine ≥3.0 mg/dL, 
hemodialysis).
Diagnosis of diabetic peripheral neuropathy
We included patients with abnormal results on a total symp-
tom score questionnaire and neurologic tests (128 Hz vibra-
tion sense test, pin prick test, 10 g monofilament test) [12]. The 
following were defined as abnormal: 
  1)  ≥2 points in total symptom score based on questions tar-
geting pain, burning sensation, dysesthesia, and anesthesia. 
  2)  ≥10-second discrepancy between subject and tester in a 
128-Hz vibration test 
  3)  ≤7 incidences of pain perception during a pin-prick test 
on the foot 
  4) ≤7 correct responses during a 10 g monofilament test 
Diagnosis of diabetic autonomic neuropathy
Diabetic autonomic neuropathy was evaluated using tilt and 
Valsalva tests as well as by monitoring heart rate response to 
deep breathing (HRDB) using a finometer model-1 (Finapres 
Medical Systems BV Co., Ltd., Amsterdam, The Netherlands). 
A quantitative sudomotor axon reflex test (QSART) was con-
ducted using QSWEAT (WR Medical Electronics Co., Stillwa-
ter, OK, USA). The severity of autonomic neuropathy was as-
sessed using a composite autonomic scoring scale (CASS) from 
0 to 10, calculated as the cumulative score of sudomotor (0 to 
3), cardiovagal (0 to 3) and adrenergic subscores (0 to 4). In 
determining the severity of autonomic neuropathy, scores of 0 
to 3, 4 to 6, and 7 to 10 were defined to be mild, moderate and 
severe, respectively [13]. A CASS score ≥1 confirmed the pres-
ence of DAN.
  The quantitative sudomotor axon reflex test assesses only 
postganglionic sudomotor function. This is a more sensitive 
test than a sympathetic skin response (SSR), which is associat-
ed with polysynaptic reactions.
Evaluation of vestibular function
Patients were given a questionnaire which elicited vertigo 
symptoms in the outpatient otolaryngology department. Pa-
tients then underwent examinations including the spontane-
ous nystagmus test, gaze nystagmus test, positional nystagmus 
test, head shaking test, Dix-Hallpike test, and the Roll test. A 
videonystagmography with caloric test was performed to re-
flect lateral semicircular canal and superior vestibular nerve 
functions. 
Statistical analysis
Data are presented as the mean±standard deviation (SD) or 
median (25th to 75th percentile). A chi-square with Fisher’s 
exact test or Mann-Whitney U test was used to detect differ-
ences between the groups. Spearman’s correlation analysis was 
used to assess correlations. Statistical analysis was performed 
using PASW version 18.0 software (SPSS Inc., Chicago, IL, 
USA). For all statistical analyses, a P value of less than 0.05 
(two-sided) was considered statistically significant.66
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RESULTS
Clinical characteristics of the subjects
The male to female ratio of the enrolled subjects was 18:17 with 
a mean age of 51.1±15.5 years. Twenty-five patients had type 2 
diabetes, which was significantly higher than the number of 
patients with type 1 diabetes. The median duration of diabetes 
was 11 years (range, 1 to 28 years). The mean BMI was 23.5± 
4.2 kg/m
2 and mean HbA1c was 9.8±2.9%. The numbers of 
the patients with dyslipidemia, diabetic retinopathy, and dia-
betic nephropathy were 18 (51.4%), 26 (74.3%), and 19 (54.3%), 
respectively (Table 1). 
Comparison of clinical characteristics based on the 
presence of diabetic autonomic neuropathy in patients with 
diabetic peripheral neuropathy
Twenty-eight patients were diagnosed with diabetic autonom-
ic neuropathy (80%). Of these, 18 exhibited mild severity and 
10 exhibited moderate severity. The numbers of patients who 
obtained abnormal results for the tilt test, Valsalva test, heart 
rate response to deep breathing, and QSART were 20 (71.4%), 
16 (57.1), 7 (25%), and 23 (82.1%), respectively. The prevalence 
of QSART was highest among these tests.
  The longer duration of diabetes and the presence of diabetic 
nephropathy were associated with a statistically significant in-
crease in the prevalence of DAN (Table 2). However, diabetic 
retinopathy and the state of glucose control as determined by 
HbA1c were not statistically related to the presence of DAN 
(Table 2). 
  The stage of chronic kidney disease and diabetic duration 
had a statistically significant relationship to the severity of DAN 
according to CASS (Table 3). Diabetes duration was signifi-
cantly correlated with CASS (r=0.45, P<0.01). None of age, 
sex, height, or BMI were linked to DAN (data not shown).
Relationship between vestibular function and autonomic 
neuropathy
The vestibular function test was performed for patients with 
dizziness. Of 19 patients who underwent the vestibular func-
tion test, 11 were diagnosed with VD (57.9%). The symptoms 
of these patients included dizziness (79%), tinnitus (37%), 
Table 1. Baseline clinical characteristics 
Characteristic Value
No. 35
Age, yr  51.1±15.5
Sex, M/F 18/17
BMI, kg/m
2 23.5±4.2
DM type, 1/2 10/25
DM duration, yr 11.4±7.5
HbA1c, % 9.8±2.9
Hypertension 12 (34.3)
Alcohol intake 11 (31.4)
Smoking 8 (22.9)
Retinopathy 26 (74.3)
Non-proliferative diabetic retinopathy 15
Proliferative diabetic retinopathy 11
Nephropathy 19 (54.3)
Microalbuminuria 6
Macroalbuminuria 13
Hyperlipidemia  18 (51.4)
Total cholesterol, mg/dL 189.4±55.3
Triglyceride, mg/dL 180.5±125.0
HDL–C, mg/dL 42.4±11.9
LDL–C, mg/dL 110.9±41.1
Creatinine clearance, mL/min 37.7±17.5
Values are presented as mean±standard deviation or number (%).
BMI, body mass index; DM, diabetes mellitus; HDL-C, high density 
lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.
Table 2. Relationships between diabetic autonomic neuropathy and diabetic duration, HbA1c, diabetic retinopathy, and diabetic 
neuropathy 
Diabetic  
autonomic 
neuropathy
Duration of diabetes, yr Diabetic  
retinopathy
HbA1c, % Diabetic  
nephropathy
≤5 6-10 11-15 ≤16 Absent Present <6.4 6.5-8.4 8.5-10.0 >10.0 Absent Present
Absent 3 (8.6) 3 (8.6) 1 (2.9) - 1 (2.9) 6 (17.1) - 1 (2.9) 2 (5.7) 4 (11.4) 6 (17.1) 1 (2.9)
Present 6 (17.1) 6 (17.1) 6 (17.1) 10 (28.6) 8 (22.9) 20 (57.1) 1 (2.9) 11 (31.4) 7 (20.0) 9 (25.7) 10 (28.6) 18 (51.4)
P=0.044 P=0.648 P=0.143 P=0.032
Values are presented as number (%).67
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with diabetic peripheral neuropathy also had DAN. This high 
rate of occurrence can be explained by the fact that enrolled 
patients had already been diagnosed with diabetic peripheral 
neuropathy, and, unlike previous studies, our study protocol 
included cardiac autonomic neuropathy, sudomotor, and ad-
renergic dysfunction based on CASS. Twenty-three patients 
(82.1%) were abnormal according to the QSART, which was 
the test with highest frequency of abnormal tests in the current 
study. To our knowledge, QSART is more sensitive than SSR 
in the diagnosis of early diabetic neuropathy. A QSART con-
ducted on a type 2 diabetic foot can predict postural hypoten-
sion, confirming its usefulness. Although the lack of equipment 
Table 3. Relationship between diabetic duration and degree of 
diabetic autonomic neuropathy (A) as well as the relationship 
between degree of diabetic chronic kidney disease and degree 
of diabetic autonomic neuropathy (B) 
Diabetic  
autonomic 
neuropathy
Duration of diabetes, yr
≤5 6-10 11-15 ≤16
a
Absent 3 (8.6) 3 (8.6) 1 (2.9) -
Mild 6 (17.1) 3 (8.6) 4 (11.4) 5 (14.3)
Moderate - 3 (8.6) 2 (5.7) 5 (14.3)
(A)
Diabetic  
autonomic 
neuropathy
Degree of chronic kidney disease, stage
Normal 
to 1 2 3 4 5
b
Normal 2 (5.7) 1 (2.9) 3 (8.6) 1 (2.9) -
Mild - 1 (2.9) 8 (22.9) 7 (20.0) 2 (5.7)
Moderate - 1 (2.9) 4 (11.4) 5 (14.3) -
Values are presented as number (%). 
aP<0.01. 
bP<0.05.
(B)
Table 4. Clinical characteristics based on results of the vestib-
ular function test
Characteristic NVF VD P value
No. 8 (42.1) 11 (57.9) NS
Age, yr  50.4±16.4 49.3±18.2 NS
Sex, M/F 6/2 4/7 NS
BMI, kg/m
2 22.0±3.6 23.7±4.4 NS
DM type, 1/2 4/4 4/7 NS
DM duration, yr 12.5±9.6 13.1±6.9 NS
HbA1c, % 9.7±2.8 10.0±2.2 NS
Hypertension  1 (12.5) 4 (36.4) NS
Retinopathy  6 (75.0) 10 (90.9) NS
Non-proliferative diabetic 
retinopathy
3 8
Proliferative diabetic reti-
nopathy
3 3
Nephropathy  3 (37.5) 6 (54.5) NS
Microalbuminuria 2 1
Macroalbuminuria 1 6
Hyperlipidemia  4 (50.0) 5 (45.5) NS
Creatinine clearance, mL/min 41.9±17.8 40.0±22.2 NS
Values are presented as mean±standard deviation or number (%).
NVF, normal vestibular function; VD, vestibular dysfunction; NS; not 
statistically significant; BMI, body mass index; DM, diabetes mellitus. 
Table 5. Relationship between diabetic autonomic neuropathy 
and vestibular dysfunction
Vestibular  
dysfunction 
Diabetic autonomic neuropathy
P value
Absent Present
Absent 3 (15.8) 5 (26.3)
0.636
Present 3 (15.8) 8 (42.1)
Values are presented as mean±standard deviation or number (%).
headache and hearing problems (21%), ear fullness (11%) and 
vertigo (5%). 
  No significant differences in age, sex, BMI, diabetic dura-
tion, state of glucose control, diabetic retinopathy, diabetic ne-
phropathy, stage of chronic kidney disease, hypertension, and 
dyslipidemia were observed between the normal vestibular 
function group and the abnormal group (Table 4).
  Eight patients were identified as having both DAN and VD 
(42.1%). No statistical significance was observed between DAN 
and VD (Table 5). 
DISCUSSION 
Diabetic peripheral neuropathy and autonomic neuropathy 
are common types of diabetic neuropathy. Diabetic peripheral 
neuropathy is frequently, although not always, accompanied 
by DAN [14].
  Diabetic peripheral neuropathy is associated with foot ul-
cers, postural instability while walking, and falls [15]. Similar-
ly, DAN and VD are associated with postural instability while 
walking and abnormal distribution of foot pressure [11,16]. If 
DAN and VD coexist with diabetic peripheral neuropathy, the 
symptoms and signs may be aggravated.
  The present study demonstrated that 28 (80%) of 35 patients 68
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precludes broad utilization, QSART can be helpful in early di-
agnosis of DAN [17,18].
  The risk factors for DAN are old age, female sex, high BMI, 
height, type of diabetes, longer morbidity and poor glycemic 
control [9]. Age, sex, height, BMI, diabetes type and glucose 
control state were not significantly related to DAN (P>0.05). 
However, the duration of diabetic morbidity was significantly 
related to DAN (P=0.044). In this study, the longer duration 
of morbidity was the more severe DAN (P=0.009). The dura-
tion of diabetes was significantly correlated with CASS (r=0.45, 
P<0.01). Diabetic nephropathy (P=0.032) and stage of chron-
ic kidney disease (P=0.003) were also significantly associated 
with DAN. 
  Klagenberg et al. [7] reported that VD prevalence was 60% 
in a study of 30 patients with type 1 diabetes. Li et al. [9] re-
ported that VD prevalence in 76 diabetic patients and 60 non-
diabetic patients was 68.4% and 8.3%, respectively, demon-
strating a significantly higher percentage in diabetics than in 
non-diabetics. Gawron et al. [8] reported that many children 
and young adults with type 1 diabetes had VD, which was 
linked to hypoglycemia frequency, duration of morbidity, and 
level of glucose control. Thus, we conducted the vestibular 
function test on 19 patients with otolaryngoloical problems of 
the 35 total patients who underwent the autonomic function 
test. Of the 19 patients, 11 (57.9%) had VD. This result was 
similar to previously described studies [7]. However, there is a 
limitation since the vestibular function test was conducted only 
on patients with dizziness. Vestibular dysfunction was not as-
sociated with age, sex, BMI, duration of diabetes, HbA1c, dia-
betic retinopathy, diabetic nephropathy, stage of chronic kid-
ney disease, hypertension or hyperlipidemia. Furthermore, 
VD was not significantly associated with DAN (P=0.636). 
  As previously described, patients with diabetic peripheral 
neuropathy have a high risk of postural instability and falls 
[15], which can be worsened by coexisting VD. However, VD 
can be ameliorated through vestibular rehabilitation treatment. 
Therefore, it is clinically important to detect VD in diabetic 
patients with peripheral neuropathy [19,20].
  The present study demonstrated that the most common 
symptom in the patients with VD was dizziness (79%), which 
can be caused by several conditions including cerebrovascular 
disease or adverse effects from drugs necessary for diabetic 
peripheral and autonomic neuropathy, hypoglycemia, or car-
diac autonomic dysfunction. Thus, dizziness in diabetic pa-
tients can be caused by not only diabetic autonomic neuropa-
thy like orthostatic hypotension, but also VD.
  Limitation in this study was the small sample size of patients 
with diabetic peripheral neuropathy. However, this study re-
vealed that patients with diabetic peripheral neuropathy had a 
high prevalence of DAN, and both diabetic nephropathy and 
the duration of diabetic morbidity were associated with DAN. 
Furthermore many of the diabetic patients with dizziness also 
had VD. Thus, if a diabetic patient of long morbidity develops 
dizziness, it is so helpful in making a differential diagnosis, 
treating, and educating patients that we should evaluate DAN 
and VD via autonomic function test and vestibular function 
test, respectively.
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